• Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa

Programação » Sessão de Encontro com Autor

Código: P 061
Apresentação: Oral, segunda opção Pôster
Área Técnica: Glaucoma
Categoria / Classificação: Oftalmologia Clinica
Região onde foi realizada a pesquisa: Sudeste

INSTITUIÇÃO ONDE FOI REALIZADO O TRABALHO:

CONEP:

AUTOR PRINCIPAL:

CO-AUTOR(ES):

TÍTULO:
THE ROLE OF THE FOURTH DRUG IN PATIENTS WITH GLAUCOMA: IS IT WORTH IT?

OBJETIVO:
Purpose: To evaluate how effective is the fourth drug regarding intraocular pressure (IOP) control in patients with primary glaucomas.

MÉTODO:
Methods: We prospectively enrolled patients with primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG) treated concomitantly with a topical prostaglandin analog, a beta-blocker, an alpha-adrenergic agonist and a carbonic anhydrase inhibitor. Patients were initially submitted to a complete ophthalmologic examination IOP was measured at 8am, 10am and 12pm. Afterwards, patients underwent a 15-day washout of the anhydrase carbonic inhibitor and had their IOP measured again at the same hours by another examiner.

RESULTADOS:
Results: A total of 25 patients were enrolled, being most women, white with a mean age of 66.4 ± 9.7 years old. The removal of the fourth drug had a statistically significant effect on the IOP peak (increase of 1.20mmHg) and mean (increase of 1.23mmHg; p<0.01)., but it did not interfere significantly with morning fluctuation of the IOP (p=0.83). Following discontinuation of the fourth drug, the IOP increased ≥2mmHg in 32% of the patients and there was a significant increase of the IOP (defined as an IOP change ≥20%) in only 5 patients (20%), being all of them above 60 years old. Age was responsible for approximately 20% of the IOP change (R2=0.19; p=0.03).

CONCLUSÕES:
Conclusions: The removal of a fourth medication does not have a significantly clinical impact on IOP control in most patients. Those who were significantly affected were all above 60 years old and age was the only significant predictive factor of IOP change.

Realização Realização - CBO
Organização/Comercialização Secretaria Executiva - ASSESSOR Secretaria Executiva - MAIS EVENTOS
Agência Oficial Agência de Viagens - Luck Viajens
Agência Web Agência Web - Inteligência Web